Truist lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $490 from $520 but keeps a Buy rating on the shares after its Q2 earnings miss. The company’s revenue topped estimates, but its Pain franchise hit a road bump with a no-go on LSR – Phase 3 lumbosacral radiculopathy study – for suzetrigine and VX-993 failure in acute pain, the analyst tells investors in a research note. Truist adds however that the early discovery program in HD has “piqued its interest”.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $455 from $494 at Stifel
- Vertex Pharmaceuticals price target lowered to $553 from $582 at UBS
- Vertex Pharmaceuticals price target lowered to $530 from $557 at BMO Capital
- Vertex price target lowered to $478 from $550 at H.C. Wainwright
- Vertex Pharmaceuticals price target lowered to $439 from $460 at Morgan Stanley